Navigation Links
Tuberculosis and neglected diseases targeted by new center

A major new centre to boost the development of drugs to tackle the foremost diseases of the developing world is to be created at the University of Dundee.

There is an urgent need for new drugs to treat infectious diseases of the developing world, such as tuberculosis (TB), malaria and African sleeping sickness. However, despite significant efforts in early stage drug discovery, there is a bottleneck when it comes to the lead optimisation stage of molecules targeting these diseases.

Lead optimisation is a key stage in the drug discovery process, where early leads are improved through cycles of design, synthesis and testing to identify potential drugs which are suitable for testing in a clinical setting. It is a labour intensive process requiring significant laboratory resource over a number of years.

To address this need Professor Paul Wyatt and colleagues at the Drug Discovery Unit (DDU) at the University of Dundee, with joint funding from the Wellcome Trust and the Bill & Melinda Gates Foundation, are establishing "A Centre of Excellence for Lead Optimisation for Diseases of the Developing World". The Dundee centre represents a 6.5million investment over five years and will create 11 new posts.

Professor Wyatt said, "One of the main aims of the Drug Discovery Unit is to make inroads into developing drugs for diseases that affected the developing world. We have the capability through the DDU to help break the bottleneck which occurs at a key stage of the drug discovery process."

The initial focus will be on TB, the world's second-leading infectious killer, disproportionately affecting developing countries; in 2010 causing 1.4 million deaths, 8.8 million new infections and 450 thousand drug-resistant TB cases. First-line therapies for TB are old and inadequate, taking six months to cure patients. The long treatment regimen contributes to high treatment default rates that can lead to increased disease transmission, drug resistance, and death.

The strategy is to identify a portfolio of TB Lead Optimisation projects through the DDU's involvement with the global HIT-TB consortium and TB Drug Accelerator Program which are working to generate drug leads through their screening programmes.

The DDU as part of HIT-TB is already identifying and optimising multiple series of related compounds which kill TB that could be taken up by the team.

Dr Richard Seabrook, Head of Business Development at the Wellcome Trust, said: "We are pleased to be co-funding with the Bill & Melinda Gates Foundation on this exciting UK project, bringing together internationally renowned experts in the biology of infectious diseases with a first-class drug discovery unit to tackle some of the world's most profound medical needs."

Contact: Roddy Isles
University of Dundee

Related medicine news :

1. First anti-tuberculosis medicine under USAID-supported PQM program achieves WHO prequalification
2. Stroke drug kills bacteria that cause ulcers and tuberculosis
3. Pain drug can kill resistant tuberculosis
4. Alarming Rise Seen in Drug-Resistant Tuberculosis
5. Dartmouth medical research closes in on new tuberculosis vaccine
6. Tuberculosis increases the risk of lung cancer mortality in the elderly
7. A better tool to diagnose tuberculosis
8. Integrated neglected tropical disease control and elimination programs: A global health best buy
9. Millions of patients still waiting for medical breakthroughs against neglected diseases
10. Open access initiative reveals drug hits for deadly neglected tropical diseases
11. Funding for neglected global diseases research at UBC exceeds $20 million
Post Your Comments:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
Breaking Medicine Technology: